A Randomized, Double-blind Phase III Clinical Study of QL1706 Versus QL1604 as Consolidation Treatment in Patients With Limited-stage Small Cell Lung Cancer Who Have Not Experienced Disease Progression After Concurrent or Sequential Chemoradiotherapy.
Latest Information Update: 06 Feb 2025
Price :
$35 *
At a glance
- Drugs Iparomlimab (Primary) ; Iparomlimab/tuvonralimab (Primary)
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Sponsors Qilu Pharmaceutical
- 30 Jan 2025 New trial record